Sign in

AIDX on Nasdaq

20/20 Biolabs, Inc.

20/20 Biolabs, Inc. is an American testing laboratories services company based in Gaithersburg.2 Its shares trade on Nasdaq under the symbol AIDX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Hypha Labs, Inc., NeoGenomics or UL Solutions Inc., or pick any stock.

  • TickerAIDX on Nasdaq2
  • IndustryServices-Testing Laboratories2
  • HeadquartersRockville, United States2
  • Incorporated inDE3
  • Business address9430 Key West Avenue, Suite 100, Rockville, Md 208503
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI5493002L38RIRZD5JQ112
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 32561452

See how the biggest companies compare on our leaderboards

O, Khan S. “Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review.” Cureus.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

29.6%Gross margin5
-162.9%Operating margin5
-182.8%Net margin5
16.7%Revenue growth, 20255

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

One Test brought in 88% of the revenue 20/20 Biolabs, Inc. broke down this way in fiscal 2025.

  1. One Test$1.8M588%up 21% from 2024
  2. Bio Check$152.0K57%down 14% from 2024
  3. CLIAx$89.4K54%up 6% from 2024
Products and services by year
Products and services20242025
One Test$1.5M$1.8M
Bio Check$177.3K$152.0K
CLIAx$84.2K$89.4K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue27¢$1.4M
  • Research and development11¢$592.6K
  • Selling, general and admin62¢$3.3M

Out of $2.0M in revenue.5 The company lost money this year.

Financial statements

Revenue5$2.0M in 2025+17% since 2024
0$1.0M$2.0M$3.0M2024: $1.8M$1.8M20242025: $2.0M$2.0M2025+17%
Gross profit5$604.5K in 2025+68% since 2024
0$200.0K$400.0K$600.0K$800.0K2024: $360.3K$360.3K20242025: $604.5K$604.5K2025+68%
Operating income5-$3.3M in 2025−41% since 2024
-$6.0M-$4.0M-$2.0M02024: -$5.7M-$5.7M20242025: -$3.3M-$3.3M2025−41%
Net income5-$3.7M in 2025−33% since 2024
-$6.0M-$4.0M-$2.0M02024: -$5.6M-$5.6M20242025: -$3.7M-$3.7M2025−33%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenues$2.0M$1.8M
Cost of revenues$1.4M$1.4M
Gross profit$604.5K$360.3K
Sales, general and administrative$3.3M$4.8M
Research and development$592.6K$1.3M
Loss on impairment of fixed assets$16.4K
Total operating expenses$3.9M$6.0M
Operating loss-$3.3M-$5.7M
Interest expense-$156.2K-$12.6K
Interest income$21.4K$79.5K
Change in fair value of derivative liabilities$7.7K
Loss on issuance of convertible note-$280.8K
Other (expense) income, net-$115$58.9K
Total other (expense) income-$407.9K$125.7K
Net loss-$3.7M-$5.6M
Basic net loss per common share (in Dollars per share)-$0.76-$1.16
Diluted net loss per common share (in Dollars per share)-$0.76-$1.16
Weighted-average common shares outstanding, basic (in Shares)4.9M shares4.8M shares
Weighted-average common shares outstanding, diluted (in Shares)4.9M shares4.8M shares

Compare 20/20 Biolabs, Inc. with another company

Corporate structure

20/20 Biolabs, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of 20/20 Biolabs, Inc.

  • 20/20 Biolabs, Inc. Rockville, Maryland, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What 20/20 Biolabs, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$581.2K5 Dec 31, 2025$581.2K5 Dec 31, 20240%
Accumulated depreciation$524.6K5 Dec 31, 2025$464.6K5 Dec 31, 2024+12.9%
Property and equipment, net$56.7K5 Dec 31, 2025$116.7K5 Dec 31, 2024−51.4%
Operating-lease assets (leased space)$605.3K5 Dec 31, 2025$772.4K5 Dec 31, 2024−21.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.0M5 Dec 31, 2025$1.8M5 Dec 31, 2024−42.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$202.3K5 Dec 31, 2025$205.5K5 Dec 31, 2024−1.6%
Finite-lived intangibles, gross$243.6K5 Dec 31, 2025$243.6K5 Dec 31, 20240%
Accumulated amortization$41.4K5 Dec 31, 2025$38.1K5 Dec 31, 2024+8.6%
Finite-lived intangibles, net$202.3K5 Dec 31, 2025$205.5K5 Dec 31, 2024−1.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$116.2K5 Dec 31, 2025$47.2K5 Dec 31, 2024+146.4%

Properties, in its own words

On March 18, 2021, we entered into a lease agreement for a new office and laboratory space totaling 5,511 square feet in Gaithersburg, Maryland. The term of the lease commenced on December 1, 2021 and expires 88 months thereafter. The initial monthly rent is $10,676 with annual increases to $17,308 for the final year of the lease. We will also pay our 7.75% pro rata portion of the property taxes, operating expenses and insurance costs and are also responsible for paying for the utilities used on the premises.

We believe that all our properties have been adequately maintained, are generally in good condition, and are suitable and adequate for our business.

Item 2 of the 10-K filed Mar 31, 2026.4

Leadership

Who has led 20/20 Biolabs, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Alan B. Bergman2026–now

Chief operating officer

  1. Jiming Zhou2026–now
Board members and other officers (3)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerAnne Shiflett named Feb 26, 202513
  • Executive OfficerJiminy Zhou named Feb 26, 202513
  • Executive Officer, DirectorJonathan Cohen named Feb 26, 202513
  • DirectorJohn W. Rollins named Feb 26, 202513
  • DirectorRichard M. Cohen named Feb 26, 202513
  • DirectorWei G Lu named Feb 26, 202513

Former names

  • 20/20 GeneSystems, Inc.Sep 22, 2015 to Feb 26, 20253
  • 20/20 GENE SYSTEMS INCJan 18, 2002 to Apr 28, 20043

Timeline

  1. Sep 18, 20268-K Shareholder vote14
  2. Sep 10, 20268-K Listing notice or transfer15
  3. Sep 2, 20268-K Regulation FD disclosure16
  4. Aug 19, 20268-K Shareholder vote17
  5. Aug 17, 20268-K Results of operations18
  6. Aug 5, 20268-K Regulation FD disclosure19
  7. Jul 22, 20268-K Entered a material agreement; Listing notice or transfer20
  8. Jul 1, 20268-K Regulation FD disclosure21
  9. May 26, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed22
  10. May 20, 20268-K Results of operations23
  11. Apr 28, 20268-K Entered a material agreement24
  12. Apr 1, 20268-K Results of operations25
  13. Aug 7, 2000Founded 20/20 Biolabs, Inc. is founded2

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202626

When it reported results

  1. Aug 17, 2026Reported quarterly or annual results18
  2. May 20, 2026Reported quarterly or annual results23
  3. Apr 1, 2026Reported quarterly or annual results25

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

97 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 12 major events, 17 insider forms, 3 large holders, 1 private raises, 61 other. The latest 20:

  1. Oct 6, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  2. Sep 18, 20268-K CURRENT REPORT EDGAR
  3. Sep 10, 20268-K CURRENT REPORT EDGAR
  4. Sep 2, 20268-K CURRENT REPORT EDGAR
  5. Aug 19, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  6. Aug 19, 20268-K CURRENT REPORT EDGAR
  7. Aug 17, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  8. Aug 17, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  9. Aug 17, 20268-K CURRENT REPORT EDGAR
  10. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  11. Aug 5, 20268-K CURRENT REPORT EDGAR
  12. Jul 22, 20268-K CURRENT REPORT EDGAR
  13. Jul 1, 20268-K CURRENT REPORT EDGAR
  14. Jun 23, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  15. Jun 23, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  16. Jun 1, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  17. May 26, 20268-K CURRENT REPORT EDGAR
  18. May 21, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  19. May 21, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  20. May 20, 202610-Q QUARTERLY REPORT EDGAR

The 97 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Jonathan Cohen,63$250.0K$325.5K30
2025Jiming Zhou,$220.0K$225.6K30
2025Michael Lebowitz,$89.6K$151.6K30
2024Chief Executive Officer$250.0K$796.3K30
2024Chief Operating Officer$220.0K$667.2K30
2024Chief Scientific Officer$76.8K$270.4K30

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$70.0K 2025–2025
Money received by yearMoney received by year, 2025–2025: $70.0K in all. Private raises (Form D) $70.0K.$0$20K$40K$60K$80K2025 · Private raises (Form D): $70.0K2025
Figures by year
YearPrivate raises (Form D)Total
2025$70.0K$70.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jan 21, 2025Raised $70,000 in a private offering of debt13 Form D: $3 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cresset Asset Management, LLC240,122$132.0K0.0%−24,246
Vanguard Fiduciary Trust Co52,087$28.6K0.0%New
Geode Capital Management, LLC49,141$27.0K0.0%New
Atlantic Union Bankshares Corp35,099$19.3K0.0%New
Vanguard Capital Management LLC24,530$13.5K0.0%New
Citadel Advisors LLC23,205$12.8K0.0%+6,978
Bank Of America Corp /de/13,024$7.2K0.0%New
Susquehanna International Group, Llp10,014$5.5K0.0%New
Mcdonald Partners LLC2,800$1.5K0.0%New
Signaturefd, LLC767$4220.0%New
Morgan Stanley283$1560.0%New
Allworth Financial LP172$950.0%+142
Toth Financial Advisory Corp100$550.0%−57
Hrt Financial LP89,273$490.0%New
UBS Group AG3$20.0%−8,311

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How 20/20 Biolabs, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAR20/20 Biolabs, Inc.1
  • CIK0001139685
  • Employer ID (EIN)57-22721074
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)8734 Services-Testing Laboratories1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address9430 Key West Avenue, Suite 100, Rockville, MD 208501
  • Mailing address15810 Gaither Road, Suite 235, Suite 235, Gaithersburg, MD 208771
  • Phone24045363391
  • Shares outstanding12,770,303 as of Aug 14, 20266
  • Public float$0 as of Jun 30, 20255
  • Auditormckennon, San Diego, California PCAOB ID 3501; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJan 18, 20021
  • Filings165 in all: 8-K (12), 3 (10), CORRESP (10), 424B3 (9), C/A (9), 253G2 (8), UPLOAD (8), 1-A/A (7)1
    All 40 form types

    1-K (7), 1-U (7), 4 (7), C-AR (7), 1-SA (6), DRS/A (6), C (5), REGDEX (5), 253G1 (3), D (3), EFFECT (3), QUALIF (3), 1-A (2), 10-Q (2), C-U (2), D/A (2), DEFA14A (2), DRS (2), PRE 14A (2), S-1 (2), S-1/A (2), SCHEDULE 13G (2), 1-A POS (1), 1-K/A (1), 10-K (1), 8-A12B (1), C-AR-W (1), CERT (1), DEF 14A (1), NT 10-Q (1), POS AM (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jun 23, 2026
    Latest 8-K (8-K) Sep 18, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.01AIDXThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks 20/20 Biolabs, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 53 risks under these headings, as written.4

  • Risks Related to Our Business and Industry
  • With limited exceptions, we have incurred losses since our inception, and we expect to continue to generate losses for the foreseeable future.
  • Our success will depend heavily on our cancer screening and longevity tests.
  • We will need to attract additional capital to scale our business but have no assurance that we can do so successfully.
  • We will spend a substantial amount of our capital on test validation, biomarker and data acquisitions, data analytics and algorithm development, but our products might not succeed in gaining widespread market acceptance.
  • The success of our diagnostic tests depends on the degree of market acceptance by physicians, patients, government agencies and others who influence medical decision making.
  • We are expecting patient self-pay to constitute a significant portion of our revenues for the foreseeable future and this revenue growth is contingent upon individuals’ willingness to pay out of pocket for our diagnostic tests.
  • The commercial potential of our longevity test is unknown and unproven.
  • The interface between the DII and our laboratory information system has not yet been implemented.
  • The viability of offering automated, tailored coupons for grocery purchases is untested and unproven by us.
  • Our CLIAx and CLIAx fund might not contribute to our growth.
  • We face substantial competition.
The other 42 risks
  • If our diagnostics tests do not perform as expected, are misused or misinterpreted, or the reliability of the technology is questioned, we could experience delayed or reduced market acceptance of the tests, increased costs and damage to our reputation. False positives or false negatives could cause harm to patients and could result in action taken against our company.
  • Our inability to manage growth could harm our business.
  • We currently manufacture our tests predominantly in one facility and perform our testing in one laboratory facility. As demand for our tests grows, we may lack adequate facility space and capabilities to meet increased processing requirements. Moreover, if these or any future facilities or our equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.
  • There are a limited number of manufacturers of molecular diagnostic equipment and related chemical reagents necessary for the provision of our diagnostic tests.
  • Our suppliers may experience development or manufacturing problems or delays that could limit the growth of our revenue or increase our losses.
  • To achieve widespread use of our diagnostic test and commercial scale, some individual consumers may need convenient access to blood draw services, but we cannot guarantee that these service providers will be willing to perform them.
  • Our capillary blood collection devices are manufactured by other companies, and we cannot guarantee that we will have a continued supply of these devices or that the costs for them will not rise significantly.
  • We have limited sales and marketing resources and few distribution resources for the commercialization of any diagnostic tests that we have developed.
  • The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline.
  • If we fail to enter into and maintain successful strategic alliances for diagnostic tests that we elect to co-develop, co-market, or out-license, we may have to reduce or delay our diagnostic test development or increase our expenditures.
  • We may become dependent on possible future collaborations to develop and commercialize many of our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business.
  • The success of our business is substantially dependent upon the efforts of our senior management team and our ability to attract additional personnel.
  • Certain jurisdictions in which we may do business may not provide the same level of legal protections and enforcement of contract and intellectual property rights to which investors are accustomed in the United States.
  • Adverse U.S. and global market, economic and political conditions, including the ongoing conflict between Ukraine and Russia, recent events in the Middle East and other events or circumstances beyond our control could have a material adverse effect on us.
  • The obligations associated with being a public company will require significant resources and management attention, and we will incur increased costs.
  • We may not complete our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective.
  • We have previously restated our financial statements and may be required to restate our financial statements in the future, which could materially and adversely affect our business, financial condition, results of operations and the trading price of our securities.
  • Risks Related to Intellectual Property
  • If we are unable to obtain and enforce patents and to protect our trade secrets, others could use our technology to compete with us, which could create undue competition and pricing pressures. There is no certainty that our pending or future patent applications will result in the issuance of patents or that our issued patents will be deemed enforceable.
  • The preparation, filing, and prosecution of patent applications can be costly and time consuming.
  • Our patents may not protect our diagnostic tests from competition.
  • If we fail to meet our obligations under various license, license option, and technology transfer agreements, we may lose our rights to key technologies or data sources on which our business depends.
  • Risks Related to Healthcare Government Regulation, Reimbursement, Product Safety and Effectiveness
  • We have relied on and expect to continue to rely on third parties to conduct studies of our diagnostics tests that will be required to meet our obligations under CLIA, CAP and/or other regulatory authorities and those third parties may not perform satisfactorily.
  • We must successfully maintain and/or upgrade our information technology systems, and our failure to do so could have a material adverse effect on our business, financial condition or results of operations.
  • Our business and operations could suffer in the event of system failures.
  • International operations could subject us to risks and expenses that could adversely impact the business and results of operations.
  • New FDA regulations of lab tests could significantly impact our commercial operations.
  • We are required to comply with federal and state laws governing the privacy of health information, and any failure to comply with these laws could result in material criminal and civil penalties.
  • We are subject to federal and state healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.
  • If we become subject to claims relating to the receipt and handling of bio-hazardous materials (including infected blood), we could incur significant cost and liability.
  • In the event that one or more lawsuits are filed against us, we could be subject to reputational risk.
  • Risks Related to Ownership of Our Common Stock
  • We may not be able to maintain a listing of our common stock on Nasdaq.
  • An active trading market may not develop or continue to be liquid, and the market price of our common stock may be volatile.
  • We have never paid cash dividends on our common stock, and we do not intend to pay dividends for the foreseeable future.
  • Future issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, could cause the market price of our common stock to decline and would result in the dilution of your holdings.
  • Future issuances of debt securities, which would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior to our common stock for the purposes of dividends and liquidating distributions, may adversely affect the level of return you may be able to achieve from an investment in our common stock.
  • Investors in our common stock may be unable to bring claims under Sections 11 and 12(a)(2) of the Securities Act due to the tracing requirement, which may limit the remedies available to investors in a direct listing.
  • If securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our common stock could be negatively affected.
  • If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.
  • We are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies and our stockholders could receive less information than they might expect to receive from more mature public companies.
  • We are also a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.
  • Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, and limit attempts by our stockholders to replace or remove our current management.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30